—
Summary‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
- The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
- The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Graft Versus Host Disease (GVHD) Overview 11
Therapeutics Development 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 19
Graft Versus Host Disease (GVHD) - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Graft Versus Host Disease (GVHD) - Products under Development by Companies 25
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 30
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 31
AbbVie Inc 31
AbGenomics International, Inc. 32
Actelion Ltd 33
Alexion Pharmaceuticals Inc 34
Amunix Operating Inc. 35
Apceth GmbH & Co. KG 36
arGEN-X BV 37
Athersys, Inc. 38
Bellicum Pharmaceuticals, Inc. 39
Bio-Cancer Treatment International Limited 40
Biogen Inc 41
Bristol-Myers Squibb Company 42
Cantex Pharmaceuticals, Inc. 43
Capricor Therapeutics, Inc. 44
Cell2B S.A. 45
CellECT Bio, Inc. 46
Cynata Therapeutics Limited 47
Cytodyn Inc. 48
Dompe Farmaceutici S.p.A. 49
Dr. Falk Pharma GmbH 50
Escape Therapeutics, Inc. 51
F. Hoffmann-La Roche Ltd. 52
Fate Therapeutics, Inc. 53
Generon (Shanghai) Corporation Ltd. 54
Gilead Sciences, Inc. 55
GlaxoSmithKline Plc 56
Idera Pharmaceuticals, Inc. 57
ImmuNext, Inc. 58
Immunomedics, Inc. 59
Incyte Corporation 60
Kadmon Corporation, LLC 61
Kamada Ltd. 62
Kiadis Pharma N.V. 63
Kymab Limited 64
Kyorin Pharmaceutical Co., Ltd. 65
MacroGenics, Inc. 66
Mallinckrodt Plc 67
Medsenic 68
Mesoblast Limited 69
Millennium Pharmaceuticals Inc 70
Neopharm Ltd. 71
Nohla Therapeutics Inc. 72
Novartis AG 73
OncoImmune, Inc. 74
OSE Immunotherapeutics 75
Pharmicell Co., Ltd. 76
REGiMMUNE Corporation 77
Rigel Pharmaceuticals, Inc. 78
Sarepta Therapeutics, Inc. 79
Seattle Genetics, Inc. 80
Seres Therapeutics, Inc. 81
Sigmoid Pharma Limited 82
Spherium Biomed S.L. 83
Takeda Pharmaceutical Company Limited 84
Targazyme, Inc. 85
Therapix Biosciences Ltd. 86
Tobira Therapeutics, Inc. 87
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685908
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140092